drugset / Trial / NCT03401671
Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK), safety and tolerability and pharmacodynamics (PD) of lanadelumab in healthy adult Japanese subjects and matched non-Hispanic healthy adult Caucasian subjects.
Timeline
- Start
- 2018-01-15
- Primary completion
- 2018-05-30
- Completion
- 2018-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanadelumab | Monoclonal antibody | 300 mg | Subcutaneous |
Indications
No indication recorded.